r-SAK Plus Ticagrelor Before PCI for STEMI Reperfusion

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current guidelines recommend thrombolytic therapy for patients with ST-elevation myocardial infarction (STEMI) if percutaneous coronary intervention (PCI) is delayed beyond 120 minutes, but this approach is associated with higher stroke rates and excessive bleeding, and previous facilitated PCI studies have shown contradictory results.

Innovation Solution

Administering a combination of recombinant staphylokinase (r-SAK) and an antiplatelet agent, such as ticagrelor, prior to PCI in STEMI patients expected to undergo PCI within 120 minutes to enhance clot dissolution and improve vessel patency without increasing bleeding risks.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If thrombolytic therapy is administered prior to PCI in patients with STEMI, then early recanalization and vessel patency are improved, but stroke rates and bleeding complications increase

Engineering Contradiction:

Improvevessel patencyVSAvoidbleeding complications

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the chemical parameter of the thrombolytic agent from conventional agents (reteplase, tenecteplase) to recombinant staphylokinase (r-SAK), which has different fibrinolytic properties and a more favorable safety profile regarding bleeding complications while maintaining recanalization efficacy

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent combines r-SAK with antiplatelet agents (ticagrelor or clopidogrel) to create a composite therapeutic regimen that addresses both thrombus dissolution and platelet aggregation, achieving synergistic effect in improving vessel patency while controlling bleeding risks through coordinated action of multiple agents

Inventive Principle:

Principle #40Composite materials

2Loss of time

If thrombolytic therapy is administered prior to PCI, then total myocardial ischemia time is reduced, but excessive bleeding occurs

Engineering Contradiction:

Improvemyocardial ischemia timeVSAvoidexcessive bleeding

Core Design Contradiction:

Loss of timeVSObject-generated harmful factors

Solution Approach 1:

The patent modifies the temporal parameter by optimizing the administration timing and dosing regimen of r-SAK to achieve rapid but controlled thrombolysis, reducing myocardial ischemia duration while preventing uncontrolled bleeding through parameter optimization

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent introduces antiplatelet agents as intermediary substances that work in conjunction with r-SAK to modulate the thrombolytic process, facilitating controlled clot dissolution while preventing excessive bleeding through balanced hemostatic modulation

Inventive Principle:

Principle #24Intermediary (Mediator)

3Reliability

If conventional thrombolytic agents are used for facilitated PCI, then recanalization is achieved, but stroke rates increase

Engineering Contradiction:

ImproverecanalizationVSAvoidstroke rates

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the chemical identity and pharmacological parameters of the thrombolytic agent to r-SAK, which demonstrates effective recanalization capability with a lower incidence of stroke compared to conventional thrombolytic agents

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The combination of r-SAK and ticagrelor improves infarct-related artery patency and reduces infarct size without increasing major bleeding, potentially leading to better immediate and long-term clinical outcomes.

Implementation Method 1

administering a combination of recombinant staphylokinase (r-SAK) and an antiplatelet agent prior to performing percutaneous coronary intervention

Methodology Applied

Scientific EffectFibrinolysis:

Implementation Method 2

the antiplatelet agent is ticagrelor

Methodology Applied

Scientific EffectPlatelet aggregation inhibition:

Data Source

PatentUS20250387459A1Method of Using r-SAK Prior to Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction

Publication Date: 2025.12.25 JIANGSU KANION GROUP CO LTD

AI summary

A method of treating acute myocardial infarction in a patient by administering to the patient a combination of r-SAK and an antiplatelet agent such as ticagrelor. The acute myocardial infarction can be ST-elevation myocardial infarction. The patient can be one who is expected to receive percutaneous coronary intervention within 120 minutes from his or her first medical contact, e.g., one who is expected to receive percutaneous coronary intervention within 120 minutes from his or her first medical contact but more than 30 minutes from his or her first medical contact. A pharmaceutical composition for use in treating acute myocardial infarction in a patient is also provided which include r-SAK and an antiplatelet agent.